CytomX Therapeutics Gross Profit 2014-2022 | CTMX

CytomX Therapeutics gross profit from 2014 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
CytomX Therapeutics Annual Gross Profit
(Millions of US $)
2021 $70
2020 $100
2019 $57
2018 $60
2017 $72
2016 $15
2015 $8
2014 $5
2013 $1
CytomX Therapeutics Quarterly Gross Profit
(Millions of US $)
2022-03-31 $17
2021-12-31 $20
2021-09-30 $18
2021-06-30 $16
2021-03-31 $16
2020-12-31 $16
2020-09-30 $18
2020-06-30 $17
2020-03-31 $50
2019-12-31 $8
2019-09-30 $11
2019-06-30 $9
2019-03-31 $29
2018-12-31 $11
2018-09-30 $13
2018-06-30 $21
2018-03-31 $14
2017-12-31 $27
2017-09-30 $24
2017-06-30 $9
2017-03-31 $12
2016-12-31 $6
2016-09-30 $3
2016-06-30 $3
2016-03-31 $2
2015-12-31 $2
2015-09-30 $2
2015-06-30 $2
2015-03-31 $2
2014-12-31
2014-09-30 $2
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.106B $0.070B
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00